Skip to Content
Merck
CN

HCYTA-60K

MILLIPLEX® Human Cytokine/Chemokine/Growth Factor Panel A

Configurable Human Cytokine/Chemokine/Growth Factor 48-Plex Panel A

Synonym(s):

Human cytokine multiplex kit, Luminex® human cytokine immunoassay, Millipore human cytokine panel

Sign In to View Organizational & Contract Pricing.

About This Item

NACRES:
NA.84
UNSPSC Code:
12161503


species reactivity

human

packaging

pkg of 1 ea

manufacturer/tradename

Milliplex®

technique(s)

multiplexing: suitable

input

plasma
serum
cell culture supernatant(s)

detection method

fluorometric (Luminex® xMAP® technology)

shipped in

wet ice

storage temp.

2-8°C

General description

Cytokines, chemokines, and growth factors are key mediatorsof immune system functions capable of signaling through autocrine, paracrine,and endocrine mechanisms. Their pleiotropic immunomodulatory propertiesallow these biomolecules to react to diverse stimuli and regulate the immuneresponse, either promoting or inhibiting inflammation.

Application

MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 48 analytes in human serum, plasma, and cell culture supernatants.

Analytes included: sCD40L, EGF, Eotaxin/CCL11, FGF-2/FGF-basic, FLT-3L, Fractalkine/CX3CL1, G-CSF, GM-CSF, GROα, IFNα2, IFNγ, IL-1α, IL-1β, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12(p70), IL-13, IL-15, IL-17A/CTLA8, IL-17E/IL-25, IL-17F, IL-18, IL-22, IL-27, IP-10/CXCL10, MCP-1/CCL2, MCP-3/CCL7, M-CSF, MDC, MIG/CXCL9, MIP-1α/CCL3, MIP-1β/CCL4, PDGF-AA, PDGF-AB/BB, RANTES/CCL5, TGFα, TNFα, TNFβ/LTA, VEGF-A

Note: RANTES cannot be plexed with other cytokines in this panel due to a required 1:100 dilution of plasma/serum samples.

Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

Features and Benefits

  • 48-Plex Power, Simplified: One kit unlocks 48 biomarkers—replaces multiple ELISAs and slashes costs.
  • More Than 20-Year Multiplexing Legacy: The original multiplex innovator—trusted by top pharma companies for critical assays.
  • Cancer, Autoimmunity, & Beyond: Power research in immunotherapy, sepsis, Alzheimer’s, and Long COVID biomarker discovery.
  • Intuitive Workflow: User-friendly protocols that require minimal training, allowing researchers to achieve publication-ready results without extensive background in multiplex assays.
  • Configurable Assay Design: Configure your panel by selecting specific analytes based on your research needs, allowing for a tailored approach that maximizes relevance and impact.
  • Robust Sample Compatibility: Verified for serum, plasma, PBMC supernatants, and cell/tissue lysates. Tested across normal and disease-state samples for broad applicability.
  • Peer-Reviewed Credibility: Frequently cited in immunology and clinical research publications. Trusted by academic institutions, CROs, and pharma companies.
  • Performance Highlights from Comparative Studies: MILLIPLEX® assays showed highest reproducibility among Luminex®-based kits in a head-to-head study and in disease profiling (e.g., ovarian cancer, sepsis), and MILLIPLEX® assays detected more significantly elevated analytes than competitors.
  • Global Support & Documentation: Backed by extensive technical documentation, protocols, and customer support.

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

For research use only. Not for use in diagnostic procedures.

Label License/Sticker for Assay Product:

By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.


Still not finding the right product?


signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

Storage Class

10 - Combustible liquids

wgk

WGK 3

Regulatory Information

新产品

This item has



Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library


Related Content

Immunology multiplex assays, like MILLIPLEX® assays, allow researchers to investigate more immune biomarkers simultaneously, saving time and resources.

Cytokine multiplex assays allow researchers to easily investigate the immune system. The MILLIPLEX® Human Cytokine/Chemokine/Growth Factor Multiplex Panels A and B are multiplex assays for cytokine detection that each offer a unique combination of 48 analytes that can be simultaneously analyzed in a small sample volume.

Discover the benefits of MILLIPLEX® multiplex assays, based on Luminex® xMAP® multiplex assay technology, that provide consistent, high-quality results and see how these multiplex biomarker Luminex® assays are being used to advance research.

View All Related Content

Yiwei Zhao et al.
Fertility and sterility, 115(4), 1044-1053 (2020-12-05)
To compare the changing peripheral levels of inflammation-related cytokine profile during a 9-day period after blastocyst transfer between women who did and did not conceive. Prospective, observational, and longitudinal study. University-affiliated hospital. Forty-seven women with infertility who were undergoing single
Carl A Pierce et al.
JCI insight, 6(9) (2021-04-07)
BACKGROUNDCoronavirus disease 2019 (COVID-19) is more benign in children compared with adults for unknown reasons. This contrasts with other respiratory viruses where disease manifestations are often more severe in children. We hypothesize that a more robust early innate immune response